Mode
Text Size
Log in / Sign up
N/A N=351

Allergens in Inner-City Schools and Childhood Asthma

Asthma

Enrolled (actual)
351
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcome: Primary: Maximum Symptom Days/14 Days — 2.7 days

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Pediatric · 4+ yrs
Sex
All
Sponsor
Boston Children's Hospital
Primary completion
Oct 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Maximum Symptom Days/14 Days
2.7
SECONDARY
Days of Slowed Activity Due to Asthma
SECONDARY
Days of Exercise-induced Symptoms
SECONDARY
Days of Cough Without an Upper Respiratory Infection
SECONDARY
Nights of Wakening Due to Asthma Symptoms
SECONDARY
Number of Hospitalizations
SECONDARY
Emergency Department Visits
SECONDARY
Unscheduled Physician/Health Care Visits
SECONDARY
Prednisone Bursts
SECONDARY
FEV1/FVC
SECONDARY
FEV1 Percent Predicted
SECONDARY
Percent Change in FEV1 After Short-acting Beta Agonist
SECONDARY
Exhaled Nitric Oxide Levels

Summary

Asthma is a disease that affects more than 12% of Americans under the age of 18 for over 14 million missed school days per year, and is the number one cause of school absences in America. Elementary school children spend 6 to 10 hours a day in school, and most of that time is spent in one classroom. The goals of this project are to provide an understanding of exposure risk factors specific to the classroom. This is critical, because the classroom environment could potentially be considered as an effective target for prevention of inner-city asthma morbidity by reducing exposures to many symptomatic children through an intervention in the school classrooms.

Eligibility Criteria

Inclusion Criteria

  • Grades K-8 the school year following spring recruitment (Ages 4-15)
  • Attend one of the schools in the fall where permission obtained for classroom sampling.
  • Able to provide assent and parent/guardian able to provide informed consent Physician-Diagnosed asthma AND Wheezing in the previous 12 months

Exclusion Criteria

  • Significant pulmonary diseases other than asthma that might influence test results or pose risks (e.g., cystic fibrosis, sarcoidosis, bronchiectasis)
  • Cardiovascular disease that requires daily medication
  • Taking a beta blocker
  • Active smoker
  • Unable to follow through with study visit or complete study procedures
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01756391). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search